Trials / Completed
CompletedNCT05497843
Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)
An Open-label, Multicenter, Phase II Study of Chiauranib Capsule in Patients With Advanced or Unresectable Soft Tissue Sarcoma Previously Failed to Standard of Care Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Chipscreen Biosciences, Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, single-arm, open-label study in patients with advanced or unresectable soft tissue sarcoma.
Detailed description
This single-arm, open-label, multiple-center clinical trial aims to study the efficacy and safety of chiauranib in the treatment of patients with advanced or unresectable soft tissue sarcoma, and to explore potential biomarkers associated with chiauranib, as well as their correlation and clinical benefits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chiauranib | 50mg, orally once daily |
Timeline
- Start date
- 2022-08-25
- Primary completion
- 2025-01-03
- Completion
- 2025-01-03
- First posted
- 2022-08-11
- Last updated
- 2025-04-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05497843. Inclusion in this directory is not an endorsement.